tofisopam
(RUJBDQSFYCKFAA-UHFFFAOYSA-N)
Structure
- SMILES
- CCC1C(=NN=C(c2c1cc(OC)c(c2)OC)c1ccc(c(c1)OC)OC)C
- Type(s)
- Experimental
- ATC code(s)
- N05BA23
- Molecular Formula:
- C22H26N2O4
- Molecular Weight:
- 382.453
- Log P:
- 3.3127
- Hydrogen Bond Acceptor:
- 6
- Hydrogen Bond Donor:
- 0
- TPSA:
- 61.64
- CAS Number(s):
- 22345-47-7
Synonym(s)
1.
tofisopam
2.
1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
3.
EGYT-341
4.
Grandaxin
5.
dextofisopam
6.
levotofisopam
7.
tofizopam
External Link(s)
Adverse Drug Event(s)
| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Acute Coronary Syndrome | OFFSIDES | ||
| 2 | Alanine Aminotransferase Increased | OFFSIDES | ||
| 3 | Apathy | OFFSIDES | ||
| 4 | Blood Glucose | OFFSIDES | ||
| 5 | Blood amylase increased | OFFSIDES | ||
| 6 | Blood cholesterol | OFFSIDES | ||
| 7 | Blood creatine phosphokinase increased | OFFSIDES | ||
| 8 | Blood potassium increased | OFFSIDES | ||
| 9 | Bone pain | OFFSIDES | ||
| 10 | Cholangiolitis | OFFSIDES | ||
| 11 | Cholelithotomy | OFFSIDES | ||
| 12 | Depressed Level of Consciousness | OFFSIDES | ||
| 13 | Gamma-Glutamyltransferase Increased | OFFSIDES | ||
| 14 | Gastroenteritis | OFFSIDES | ||
| 15 | Leukopenia neonatal | OFFSIDES | ||
| 16 | Lymphocyte stimulation test positive | OFFSIDES | ||
| 17 | Nasopharyngitis | OFFSIDES | ||
| 18 | Neutrophil count decreased | OFFSIDES | ||
| 19 | Oculomucocutaneous syndrome | OFFSIDES | ||
| 20 | Overdose | OFFSIDES | ||
| 21 | Platelet count abnormal | OFFSIDES | ||
| 22 | Polymyositis | OFFSIDES | ||
| 23 | Poriomania | OFFSIDES | ||
| 24 | Rhabdomyolysis | OFFSIDES | ||
| 25 | Self Mutilation | OFFSIDES | ||
| 26 | Vertebral artery occlusion | OFFSIDES |
Powered by :
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.